Benign Prostatic Hyperplasia: Medical Therapy Comparison and Surgical Options
Diagnosis and Severity Assessment
The International Prostate Symptom Score (IPSS) quantifies severity: mild (0-7), moderate (8-19), and severe (20-35). Initial evaluation includes digital rectal examination, urinalysis, serum creatinine, PSA (to assess prostate volume and exclude malignancy), and post-void residual measurement. Uroflowmetry (peak flow rate below 10 mL/s suggests significant obstruction) adds diagnostic precision. Transrectal or transabdominal ultrasound provides prostate volume measurement, which guides treatment selection: alpha-blockers are effective regardless of prostate size, while 5-alpha reductase inhibitors (5ARIs) and several surgical options are most beneficial for prostates above 30-40 mL.
Alpha-Blocker Therapy
Alpha-1-adrenergic antagonists provide the most rapid symptomatic relief, with IPSS improvement of 4-6 points within 1-2 weeks. Tamsulosin 0.4 mg daily is the most commonly prescribed agent due to uroselective alpha-1A/1D receptor binding and fewer cardiovascular side effects than nonselective agents. Silodosin 8 mg daily offers the highest alpha-1A selectivity with a 6-7 point IPSS improvement but higher rates of retrograde ejaculation (28% versus 11% for tamsulosin). Alfuzosin 10 mg daily (extended-release) and doxazosin 4-8 mg daily are alternatives. The CombAT trial and MTOPS trial established that all alpha-blockers have comparable efficacy, and selection should be based on side effect profiles and patient priorities (sexual function, orthostatic tolerance).
5-Alpha Reductase Inhibitors and Combination Therapy
Finasteride 5 mg daily and dutasteride 0.5 mg daily reduce prostate volume by 20-25% over 6-12 months and decrease the risk of acute urinary retention and need for surgery by approximately 50% (PLESS trial for finasteride; ARIA/ARIB trials for dutasteride). Efficacy is greatest for prostates above 40 mL (or PSA above 1.5 ng/mL as a surrogate). The MTOPS and CombAT trials demonstrated combination alpha-blocker plus 5ARI is superior to monotherapy: CombAT showed combination therapy reduced clinical progression by 66% versus tamsulosin alone (HR 0.34, p<0.001) over 4 years. Side effects include decreased libido (5-7%), erectile dysfunction (5-8%), and decreased ejaculate volume (2-4%).
Sponsored
Minimally Invasive Surgical Therapies
Prostatic urethral lift (UroLift) mechanically retracts obstructing lateral lobes, improving IPSS by 11 points at 5 years while preserving sexual function (no retrograde ejaculation or erectile dysfunction). Eligibility is limited to prostates 30-80 mL without a prominent median lobe. Water vapor thermal therapy (Rezum) uses convective radiofrequency-generated steam to ablate prostate tissue, with 5-year data showing sustained IPSS improvement of 47% and Qmax improvement of 50%, with low rates of de novo erectile dysfunction (3%) and no ejaculatory dysfunction. Aquablation (robotic waterjet ablation) guided by real-time TRUS provides size-independent tissue removal; the WATER and WATER II trials demonstrated efficacy for prostates 30-150 mL with a 2-year surgical retreatment rate of 4.3%.
TURP and Laser Enucleation: The Durability Standards
Transurethral resection of the prostate (TURP) remains the reference standard surgical treatment for prostates 30-80 mL, with IPSS improvement of 70% and Qmax improvement of 120% at 5 years. Reoperation rates are 5-8% at 10 years. Holmium laser enucleation of the prostate (HoLEP) is size-independent, applicable even to prostates above 200 mL, with comparable symptom improvement and lower transfusion rates (0.1% versus 2-5% for TURP). The GOLIATH trial confirmed HoLEP noninferior to TURP at 2 years. Selection among surgical options depends on prostate size, anatomy (median lobe presence), patient priorities regarding sexual function, operator expertise, and candidacy for anesthesia.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.